[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ES2233931T3 - Fenilacetato y derivados, solos o en combinacion con otros compuestos, contra estados neoplasicos y otros trastornos. - Google Patents

Fenilacetato y derivados, solos o en combinacion con otros compuestos, contra estados neoplasicos y otros trastornos.

Info

Publication number
ES2233931T3
ES2233931T3 ES94930694T ES94930694T ES2233931T3 ES 2233931 T3 ES2233931 T3 ES 2233931T3 ES 94930694 T ES94930694 T ES 94930694T ES 94930694 T ES94930694 T ES 94930694T ES 2233931 T3 ES2233931 T3 ES 2233931T3
Authority
ES
Spain
Prior art keywords
phenylacetate
methods
derivatives
alone
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94930694T
Other languages
English (en)
Inventor
Dvorit Samid
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/135,661 external-priority patent/US5635532A/en
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Application granted granted Critical
Publication of ES2233931T3 publication Critical patent/ES2233931T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Reproductive Health (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)

Abstract

SE PRESENTAN COMPOSICIONES Y METODOS PARA EL TRATAMIENTO DE DIFERENTES DESORDENES MEDIANTE LA ADMINISTRACION DE UNA CANTIDAD TERAPEUTICAMENTE EFECTIVA DE FENILACETATO O DE DERIVADOS FARMACOLOGICAMENTE ACEPTABLES DEL MISMO O DE DERIVADOS DEL MISMO SOLOS O EN COMBINACION O EN CONJUNCION CON OTROS AGENTES TERAPEUTICOS, INCLUYENDO RETINOIDES, HIDROXIUREA Y FLAVONOIDES. SE PRESENTAN METODOS INTRAVESICULA PARA EL TRATAMIENTO DEL FENILACETATO DE CANCERES. TAMBIEN SON ASPECTOS DE ESTA INVENCION SALES FARMACOLOGICAMENTE ACEPTABLES SOLAS O EN COMBINACION Y METODOS PARA EVITAR EL SIDA Y LAS CONDICIONES MALIGNAS, E INDUCIR LA DIFERENCIACION CELULAR. SE PRESENTA UN PRODUCTO COMO UNA PREPARACION COMBINADA DE FENILACETATO Y UN RETINOIDE, HIDROXIUREA O FLAVONOIDE (DIFERENTE DEL INHIBIDOR DE LA VIA DEL MEVALONATO) PARA SU USO EN EL TRATAMIENTO SIMULTANEO, SEPARADO O SECUENCIAL DE UNA CONDICION NEOPLASTICA EN UN SUJETO. TAMBIEN SE PRESENTAN METODOS PARA MODULAR EL METABOLISMO DE LOS LIPIDOS Y/O REDUCIR LOS TRIGLICERIDOS EN SANGRE EN UN SUJETO USANDO FENILACETATO.
ES94930694T 1993-10-12 1994-10-12 Fenilacetato y derivados, solos o en combinacion con otros compuestos, contra estados neoplasicos y otros trastornos. Expired - Lifetime ES2233931T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/135,661 US5635532A (en) 1991-10-21 1993-10-12 Compositions and methods for therapy and prevention of pathologies including cancer, AIDS and anemia
US08/207,521 US5605930A (en) 1991-10-21 1994-03-07 Compositions and methods for treating and preventing pathologies including cancer

Publications (1)

Publication Number Publication Date
ES2233931T3 true ES2233931T3 (es) 2005-06-16

Family

ID=26833540

Family Applications (2)

Application Number Title Priority Date Filing Date
ES94930694T Expired - Lifetime ES2233931T3 (es) 1993-10-12 1994-10-12 Fenilacetato y derivados, solos o en combinacion con otros compuestos, contra estados neoplasicos y otros trastornos.
ES04030912T Expired - Lifetime ES2303624T3 (es) 1993-10-12 1994-10-12 Fenilacetato y derivados solos o en combinacion con otros compuestos contra afecciones neoplasicas y otros trastornos.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES04030912T Expired - Lifetime ES2303624T3 (es) 1993-10-12 1994-10-12 Fenilacetato y derivados solos o en combinacion con otros compuestos contra afecciones neoplasicas y otros trastornos.

Country Status (15)

Country Link
US (4) US5605930A (es)
EP (2) EP0725635B1 (es)
JP (5) JP3628694B2 (es)
AT (2) ATE285760T1 (es)
AU (1) AU702051B2 (es)
CA (1) CA2173976C (es)
DE (2) DE69434211T2 (es)
DK (1) DK1523982T3 (es)
ES (2) ES2233931T3 (es)
HK (1) HK1077204A1 (es)
IL (1) IL111251A (es)
NZ (1) NZ275673A (es)
PT (2) PT725635E (es)
SI (1) SI1523982T1 (es)
WO (1) WO1995010271A2 (es)

Families Citing this family (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6204370B1 (en) * 1992-03-11 2001-03-20 Institute Of Virology, Slovak Academy Of Sciences MN gene and protein
US6407082B1 (en) 1996-09-13 2002-06-18 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of a vitamin D compound
RO115498B1 (ro) * 1993-10-29 2000-03-30 Univ Boston Metoda de tratament a neoplasmului
US5981597A (en) * 1995-02-13 1999-11-09 Trustees Of The University Of Pennsylvania Differentiating agents for the treatment of inflammatory intestinal diseases
US5705352A (en) * 1995-02-27 1998-01-06 Eli Lilly And Company Multiple drug resistance gene of Aspergillus fumigatus
US5932619A (en) * 1995-10-13 1999-08-03 Rush-Presbyterian, St. Luke's Medical Center Method for preventing sexually transmitted diseases
US6226620B1 (en) * 1996-06-11 2001-05-01 Yeong Kuang Oon Iterative problem solving technique
US6197743B1 (en) 1996-07-26 2001-03-06 The Trustees Of Boston University Compositions and methods for the treatment of viral disorders
EP1886677A1 (en) * 1996-07-26 2008-02-13 Susan P. Perrine Use of an inducing agent for the treatment of blood, viral and cellular disorders
ATE462433T1 (de) * 1996-12-11 2010-04-15 Dana Farber Cancer Inst Inc Methoden und pharmazeutische zusammensetzungen zur inhibition des tumorwachstums
PL335506A1 (en) * 1997-03-04 2000-04-25 Wisconsin Alumni Res Found Method of inhibiting neoplasm growth by means of combinations of isoprenoids and statins
US6110955A (en) * 1997-03-11 2000-08-29 Beacon Laboratories, Inc. Metabolically stabilized oxyalkylene esters and uses thereof
US5939455A (en) * 1997-03-11 1999-08-17 Beacon Laboratories, Inc. Therapeutic augmentation of oxyalkylene diesters and butyric acid derivatives
EP2322216A1 (en) * 1997-03-21 2011-05-18 Chugai Seiyaku Kabushiki Kaisha A preventive or therapeutic agent for sensitized T cell-mediated diseases comprising IL-6 antagonist as an active ingredient
WO1999007418A2 (en) * 1997-08-11 1999-02-18 Allergan Sales, Inc. Sterile bioerodible implant device with improved biocompatability and method
US6242196B1 (en) 1997-12-11 2001-06-05 Dana-Farber Cancer Institute Methods and pharmaceutical compositions for inhibiting tumor cell growth
AU774861B2 (en) * 1998-02-11 2004-07-08 Douglas V Faller Compositions and methods for the treatment of cystic fibrosis
US6258849B1 (en) 1998-07-23 2001-07-10 Stanislaw R. Burzynski Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate
US6355677B1 (en) * 1998-09-28 2002-03-12 The Johns Hopkins University Adrenoleukodystrophy treatments and drug screening
US6127419A (en) * 1998-11-23 2000-10-03 Burzynski; Stanislaw R. Phenylacetic acid compositions for treating or preventing atherosclerosis and restenosis
CN100448454C (zh) * 1998-12-07 2009-01-07 艾科斯迈特技术公司 用于癌症治疗的天然植物精油组合物及方法
EP1162884A4 (en) * 1999-03-19 2002-07-24 Vertex Pharma LOW-DOSE ORAL COMPOSITIONS OF BUTYRATE COMPOSITIONS
WO2000067737A2 (en) * 1999-05-07 2000-11-16 The Brigham And Women's Hospital, Inc. USE OF HMGCoA REDUCTASE INHIBITORS IN THE PREVENTION OF DISEASES WHOSE PATHOGENESIS IS DEPENDENT ON NEOVASCULARIZATION
US6624194B1 (en) * 1999-06-04 2003-09-23 Metabolex, Inc. Use of (−) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia
US7576131B2 (en) * 1999-06-04 2009-08-18 Metabolex, Inc. Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia
US6262118B1 (en) 1999-06-04 2001-07-17 Metabolex, Inc. Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes and hyperlipidemia
US6403646B1 (en) 1999-06-30 2002-06-11 David H. Perlmutter Method for the treatment of alpha-1-antitrypsin deficiency and related pathologies
US6733779B2 (en) * 1999-08-26 2004-05-11 L. Dean Parks Method of treating benign prostatic hyperplasia and other benign prostate conditions
US6458838B1 (en) * 1999-09-28 2002-10-01 Johns Hopkins University Adrenoleukodystrophy treatments
US6864355B1 (en) 2000-05-02 2005-03-08 Yale University Inhibition of NF-κB activation by blockade of IKKβ-NEMO interactions at the NEMO binding domain
US6534537B2 (en) * 2000-01-07 2003-03-18 Kenneth Weisman Use of HMG-COA reductase inhibitors to prevent and treat BPH
WO2001052789A2 (en) 2000-01-20 2001-07-26 The Brigham And Women's Hospital, Inc. PAX8-PPARη NUCLEIC ACID MOLECULES AND POLYPEPTIDES AND USES THEREOF
WO2001066144A2 (en) * 2000-03-08 2001-09-13 Rhode Island Hospital, A Lifespan Partner Antineoplastic combination comprising an inhibitor of angiogenesis and an inhibitor of dna topoisomerase i enzyme activity
US6987131B1 (en) * 2000-06-26 2006-01-17 Burzynski Stanislaw R Phenylacetic acid compositions for treating or preventing hypercholesterolemia
ATE448194T1 (de) 2000-08-29 2009-11-15 Biocon Ltd Verwendung einer pharmazeutischen zusammensetzung mit einem para-aminophenylessigsäurederivat für die behandlung von entzündlichen erkrankungen des magen-darmtrakts
US6538030B2 (en) 2000-09-20 2003-03-25 Yih-Lin Chung Treating radiation fibrosis
US7037652B2 (en) 2000-11-28 2006-05-02 Wyeth Expression analysis of KIAA nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer
WO2002044420A2 (en) * 2000-11-28 2002-06-06 Wyeth Expression analysis of smarc nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer
BR0115715A (pt) * 2000-11-28 2004-02-03 Wyeth Corp Análise de expressão de ácidos nucleìcos e polipeptìdeos úteis na diagnose e tratamento de câncer da próstata
US7033611B2 (en) * 2001-02-23 2006-04-25 Biora Bioex Ab Matrix protein compositions for guided connective tissue growth
US7842727B2 (en) * 2001-03-27 2010-11-30 Errant Gene Therapeutics, Llc Histone deacetylase inhibitors
US7312247B2 (en) * 2001-03-27 2007-12-25 Errant Gene Therapeutics, Llc Histone deacetylase inhibitors
US8026280B2 (en) 2001-03-27 2011-09-27 Errant Gene Therapeutics, Llc Histone deacetylase inhibitors
US6495719B2 (en) 2001-03-27 2002-12-17 Circagen Pharmaceutical Histone deacetylase inhibitors
US8048924B2 (en) 2001-08-29 2011-11-01 Biocon Limited Methods and compositions employing 4-aminophenylacetic acid compounds
EP1291015A1 (en) 2001-09-10 2003-03-12 Lunamed AG Dosage forms having prolonged active ingredient release
MY131170A (en) * 2002-03-28 2007-07-31 Nissan Chemical Ind Ltd Therapeutic agent for glomerular disease
DE10313900A1 (de) * 2002-04-10 2003-10-30 Haemato Basics Gmbh Vitamin-Kombination zum Schutz bei Chemo- oder/ und Strahlungstherapie maligner Tumoren
US20040229948A1 (en) * 2002-04-12 2004-11-18 Summar Marshall L. Method for preventing hepatic encephalopathic episodes
US20030206946A1 (en) * 2002-04-26 2003-11-06 Yih-Lin Chung Methods for therapy of connective tissue disease
US8163764B2 (en) * 2002-04-26 2012-04-24 Asan Laboratories Company (Cayman) Limited Skincare methods
US8846039B2 (en) * 2002-04-26 2014-09-30 Asan Laboratories Company (Cayman), Limited Method for ameliorating pruritus
US8883148B2 (en) * 2002-04-26 2014-11-11 Asan Laboratories Company (Cayman), Limited Prevention of joint destruction
US6809118B2 (en) * 2002-07-25 2004-10-26 Yih-Lin Chung Methods for therapy of radiation cutaneous syndrome
US8946295B2 (en) * 2002-07-25 2015-02-03 Sunny Pharmtech Inc. Histone hyperacetylating agents for promoting wound healing and preventing scar formation
US20060275370A1 (en) * 2002-07-25 2006-12-07 Yih-Lin Chung Method and compositions for treatment of epithelial damage
AU2002259142A1 (en) * 2002-05-03 2003-11-17 Thomas Jefferson University Method to follow progression of kidney disease
GB0210741D0 (en) * 2002-05-10 2002-06-19 Medical Res Council Methods of therapy
AU2003243272A1 (en) * 2002-05-22 2003-12-12 Errant Gene Therapeutics, Llc Histone deacetylase inhibitors based on alpha-ketoepoxide compounds
US7115563B2 (en) * 2002-05-29 2006-10-03 Insignion Holding Limited Composition and its therapeutic use
CA2506504A1 (en) * 2002-11-20 2004-06-03 Errant Gene Therapeutics, Llc Treatment of lung cells with histone deacetylase inhibitors
US7199259B2 (en) * 2003-06-20 2007-04-03 Metabolex, Inc. Resolution of α-(phenoxy)phenylacetic acid derivatives
US20050100537A1 (en) * 2003-11-10 2005-05-12 Evans Gregory S. Methods and kits for reducing cellular damage, inhibiting free radical production, and scavenging free radicals in mammals
US20050182122A1 (en) * 2003-11-20 2005-08-18 Bello Carlo L. Method of treating abnormal cell growth using indolinone compounds
US8617550B2 (en) * 2003-12-19 2013-12-31 Chugai Seiyaku Kabushiki Kaisha Treatment of vasculitis with IL-6 antagonist
EP1555021A1 (en) * 2004-01-16 2005-07-20 National Health Research Institutes Combinations of a mevalonate pathway inhibitor and a PPAR-gamma agonist for treating cancer
CN102018693B (zh) 2004-01-22 2013-03-13 迈阿密大学 局部辅酶q10制剂及其使用方法
WO2005072462A2 (en) * 2004-01-28 2005-08-11 Charles Shih Enhancement of anti-androgenic activity by a combination of inhibitors targeting different steps of a steroid-dependent gene activation pathway and uses thereof
US20060084704A1 (en) * 2004-01-28 2006-04-20 Charles Shih Methods and compositions for enhancing degradation of nuclear receptor transcription factors and uses thereof
US20070264241A1 (en) * 2004-02-25 2007-11-15 Ekstrom Tomas J Compounds for Enhanced Cancer Therapy
WO2005115384A2 (en) * 2004-05-25 2005-12-08 Metabolex, Inc. Bicyclic, substituted triazoles as modulators of ppar and methods of their preparation
CN1997633A (zh) * 2004-05-25 2007-07-11 麦它波莱克斯股份有限公司 作为ppar调节剂的取代的三唑及其制备方法
PL1773767T3 (pl) 2004-07-07 2016-07-29 Biocon Ltd Synteza azowo związanych związków immunoregulacyjnych
US20060073213A1 (en) * 2004-09-15 2006-04-06 Hotamisligil Gokhan S Reducing ER stress in the treatment of obesity and diabetes
WO2006031931A2 (en) * 2004-09-15 2006-03-23 The President And Fellows Of Harvard College Reducing er stress in the treatment of obesity and diabetes
WO2006052916A2 (en) * 2004-11-08 2006-05-18 Errant Gene Therapeutics, Inc. Histone deacetylase inhibitors
US8377918B2 (en) * 2005-01-31 2013-02-19 ACC Therapeutics Inc Apigenin for chemoprevention, and chemotherapy combined with therapeutic reagents
US7666676B2 (en) * 2005-05-16 2010-02-23 St. Joseph's Children's Hospital Modulating cancer cell characteristics
CA2619568A1 (en) * 2005-08-19 2007-03-01 Government Of The United States Of America, Represented By The Secretary , Department Of Health And Human Services Topical formulations of histone deacetylase inhibitors and methods of using the same
KR100745821B1 (ko) * 2005-09-23 2007-08-02 에스케이 주식회사 소디움 페닐부티레이트를 이용한 약물 또는 알코올 중독,또는 조울증의 예방 및 치료용 의약 조성물
US7714131B2 (en) * 2005-09-23 2010-05-11 Metabolex, Inc. Process for the stereoselective preparation of (−)-halofenate and derivatives thereof
MX2009007345A (es) 2007-01-08 2010-02-22 Androscience Corp Compuestos con (fenil sustituido), con restos de propenal, sus derivados, actividad biologica y uso del mismo.
US9000222B2 (en) 2007-01-08 2015-04-07 Androscience Corporation Compounds with (1E, 6E)-1,7-bis-(3,4-dimethoxyphenyl)-4,4-disubstituted-hepta-1,6-diene-3,5-dione structural scaffold, their biological activity, and uses thereof
US8710272B2 (en) 2007-01-08 2014-04-29 Androscience Corporation Compounds with (1 E, 6E)-1,7-bis-(3,4-dimethoxyphenyl)-4,4-disubstituted-hepta-1,6-diene-3,5-dione structural scaffold, their biological activity, and uses thereof
US20080187952A1 (en) * 2007-02-05 2008-08-07 Wisconsin Alumni Research Foundation Biomarkers of Ionizing Radiation Response
MX2010001125A (es) 2007-07-31 2010-09-30 Androscience Corp Composiciones incluyendo receptor androgeno de degradacion (ard) ponteciadores y metodos de tratamiento profilactico o terapeutico de trastornos de la piel y la caida de cabello.
JP2009078977A (ja) * 2007-09-25 2009-04-16 Japan Health Science Foundation 心筋の小胞体ストレス抑制剤
CN101959429B (zh) 2008-01-08 2014-09-10 阿克塞利亚制药公司 抗微生物肽系统的激动剂
KR20100136997A (ko) 2008-04-11 2010-12-29 싸이토테크 랩스, 엘엘씨 암세포에서 아폽토시스를 유도하는 방법 및 용도
US9063122B2 (en) * 2008-10-17 2015-06-23 Alfredo Gallegos Biomodulators for treatment or prevention of disease
WO2010105112A1 (en) * 2009-03-11 2010-09-16 Hemaquest Pharmaceuticals, Inc. Detection of short-chain fatty acids in biological samples
WO2010120931A2 (en) * 2009-04-14 2010-10-21 University Of Medicine And Dentistry Of New Jersey E2f as a target for treatment of hormone refractory prostate cancer
KR101923354B1 (ko) * 2009-05-04 2018-11-28 프로메틱 파마 에스엠티 리미티드 치환된 방향족 화합물 및 그의 약학적 용도
MX351083B (es) 2009-05-11 2017-09-29 Berg Llc Métodos para el tratamiento de trastornos oncológicos usando cambiadores epimetabólicos, moléculas intracelulares multidimensionales, o influenciadores ambientales.
US20110086869A1 (en) 2009-09-24 2011-04-14 The Trustees Of Boston University Methods for treating viral disorders
US8618068B2 (en) 2009-12-08 2013-12-31 Trustees Of Boston University Methods and low dose regimens for treating red blood cell disorders
US20110245154A1 (en) 2010-03-11 2011-10-06 Hemaquest Pharmaceuticals, Inc. Methods and Compositions for Treating Viral or Virally-Induced Conditions
PT3443957T (pt) * 2010-10-27 2020-12-18 Liminal Biosciences Ltd Compostos e composições para o tratamento do cancro
CA2832324C (en) 2011-04-04 2022-03-15 Berg Llc Methods of treating central nervous system tumors
EP2599482A1 (en) 2011-11-30 2013-06-05 Lunamed AG Low dose therapeutic use of glyceryl tri-(4-phenylbutyrate)
EP2599767A1 (en) 2011-11-30 2013-06-05 Lunamed AG Phenylbutyl-derivatives
EP2607367A1 (en) 2011-12-21 2013-06-26 Lunamed AG Glycerol phenyl butyrate derivatives
EP2607366A1 (en) 2011-12-21 2013-06-26 Lunamed AG Glycerol phenyl butyrate esters
CN103417521B (zh) * 2012-05-15 2015-06-10 北京京朋汇药业研究发展有限公司 高原儿茶酸在制备抗肿瘤药物中的用途
EP2716167A1 (en) * 2012-10-02 2014-04-09 Lunamed AG Non-pharmaceutical composition comprising short chain fatty acids
WO2014138391A1 (en) * 2013-03-06 2014-09-12 The Johns Hopkins University Targeting glutamine metabolism in brain tumors
WO2014168993A1 (en) 2013-04-08 2014-10-16 Berg Llc Treatment of cancer using coenzyme q10 combination therapies
JP6595478B2 (ja) 2013-09-04 2019-10-23 バーグ エルエルシー コエンザイムｑ１０の連続注入によるがんの治療方法
JP7136807B2 (ja) 2017-04-17 2022-09-13 ザ・ユニバーシティ・オブ・シカゴ ヒトの健康及び疾患の治療用途向けの短鎖脂肪酸の腸への送達用ポリマー材料
KR20220034736A (ko) 2019-05-31 2022-03-18 비락타 서브시디어리 인크. 히스톤 데아세틸라제 억제제를 사용하여 바이러스 관련 암을 치료하는 방법
US11633554B1 (en) * 2019-06-11 2023-04-25 Luca Puviani Adaptive systems and methods for delivery of a medicament
KR102135026B1 (ko) * 2019-11-22 2020-07-17 한국지질자원연구원 시계열 지표수 흐름 거동 예측방법
CN114184693B (zh) * 2021-10-14 2023-10-13 重庆医科大学 4-羟苯乙酸作为标志物在制备脓毒症脑病的诊断试剂盒中的应用
WO2024165757A1 (en) 2023-02-10 2024-08-15 Ludwig-Maximilians-Universität München Oral phenylbutyrate for treatment of human 4-repeat tauopathies

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4028404A (en) * 1967-07-31 1977-06-07 Allen & Hanburys Limited Acetic acid derivatives
US3998966A (en) * 1971-11-04 1976-12-21 Syntex Corporation Anti-inflammatory, analgesic, anti-pyretic and anti-pruritic 6-substituted 2-naphthyl acetic acid derivative-containing compositions and methods of use thereof
CH567477A5 (es) * 1972-03-10 1975-10-15 Ciba Geigy Ag
IN140121B (es) * 1974-01-14 1976-09-18 Isf Spa
GB1511645A (en) * 1974-05-31 1978-05-24 Univ Ife Sickle cell anaemia treatment
FR2416214A1 (fr) * 1978-02-02 1979-08-31 Inst Rech Scient Irs Derives d'acide naphtyl-1 acetique, leur procede de preparation et leur application therapeutique
US4282214A (en) * 1978-07-31 1981-08-04 The Procter & Gamble Company Phenylacetate anti-inflammatory composition
AU528532B2 (en) * 1978-12-18 1983-05-05 Mcniel Laboratories Acetaminophen analgesic potentiation
US4470970A (en) * 1981-07-02 1984-09-11 Burzynski Stanislaw R Purified antineoplaston fractions and methods of treating neoplastic disease
IE54269B1 (en) * 1981-12-30 1989-08-02 Ici America Inc Pharmaceutically active phenylcarboxylic acid derivatives
JPS58194814A (ja) * 1982-05-11 1983-11-12 Nippon Shinyaku Co Ltd 免疫調節作用を有する薬剤
US4457942A (en) * 1982-08-20 1984-07-03 Brusilow Saul W Process for waste nitrogen removal
DE3440288C2 (de) * 1984-11-05 1987-03-12 Gergely, Gerhard, Dr.-Ing., Wien Pharmazeutische Zubereitung mit einem Gehalt an Ibuprofen sowie Verfahren zu ihrer Herstellung
EP0212746B1 (en) * 1985-08-16 1991-04-10 The Procter & Gamble Company Drug particles having constant release
GB8524421D0 (en) * 1985-10-03 1985-11-06 Boots Co Plc Therapeutic agents
GB8528195D0 (en) * 1985-11-15 1985-12-18 Boots Co Plc Therapeutic compositions
GB8606762D0 (en) * 1986-03-19 1986-04-23 Boots Co Plc Therapeutic agents
CH669523A5 (es) * 1986-06-25 1989-03-31 Mepha Ag
GB8623557D0 (en) * 1986-10-01 1986-11-05 Boots Co Plc Therapeutic agents
US4788220A (en) * 1987-07-08 1988-11-29 American Home Products Corporation (Del.) Pediatric ibuprofen compositions
US4999226A (en) * 1988-06-01 1991-03-12 Merrell Dow Pharmaceuticals Inc. Pharmaceutical compositions for piperidinoalkanol-ibuprofen combination
US5032384A (en) * 1989-01-27 1991-07-16 Block Drug Company, Inc. Compositions and method for the treatment of disease
US4975465A (en) * 1989-03-28 1990-12-04 American Home Products Corporation Orally administrable ibuprofen compositions
NZ234143A (en) * 1989-06-28 1991-10-25 Mcneil Ppc Inc Aqueous pharmaceutical suspension formulation for administering substantially insoluble pharmaceutical agents
GB8920693D0 (en) * 1989-09-13 1989-10-25 Nicholas Kiwi Pty Ltd Non-effervescent ibuprofen compositions
US5204367A (en) * 1990-02-16 1993-04-20 Harbor Branch Oceanographic Institution, Inc. Novel antiviral and anti-leukemia terpene hydroquinones and methods of use
US5244922A (en) * 1990-09-04 1993-09-14 Burzynski Stanislaw R Methods for treating viral infections
EP0567613B1 (en) * 1991-10-21 2002-02-20 The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services Compositions for therapy and prevention of cancer

Also Published As

Publication number Publication date
EP0725635A1 (en) 1996-08-14
US5883124A (en) 1999-03-16
US5852056A (en) 1998-12-22
AU7973794A (en) 1995-05-04
ES2303624T3 (es) 2008-08-16
DE69435086T2 (de) 2009-03-19
US5605930A (en) 1997-02-25
US5843994A (en) 1998-12-01
CA2173976A1 (en) 1995-04-20
JP2005139208A (ja) 2005-06-02
JP2001253821A (ja) 2001-09-18
EP1523982B1 (en) 2008-03-12
WO1995010271A2 (en) 1995-04-20
NZ275673A (en) 2000-09-29
EP1523982A3 (en) 2005-04-27
ATE388699T1 (de) 2008-03-15
JP2005139209A (ja) 2005-06-02
EP1523982A2 (en) 2005-04-20
ATE285760T1 (de) 2005-01-15
WO1995010271A3 (en) 1995-06-22
PT725635E (pt) 2005-05-31
DE69434211T2 (de) 2005-12-15
DK1523982T3 (da) 2008-07-14
DE69435086D1 (de) 2008-04-24
HK1077204A1 (en) 2006-02-10
EP0725635B1 (en) 2004-12-29
JP3628694B2 (ja) 2005-03-16
IL111251A (en) 2004-06-20
JPH09506079A (ja) 1997-06-17
JP2003119130A (ja) 2003-04-23
SI1523982T1 (sl) 2008-10-31
AU702051B2 (en) 1999-02-11
DE69434211D1 (de) 2005-02-03
IL111251A0 (en) 1994-12-29
CA2173976C (en) 2008-02-19
PT1523982E (pt) 2008-06-25

Similar Documents

Publication Publication Date Title
ES2233931T3 (es) Fenilacetato y derivados, solos o en combinacion con otros compuestos, contra estados neoplasicos y otros trastornos.
ES2144119T3 (es) Uso de inhibidores de la ciclooxigenasa no esteroideos para la fabricacion de un medicamento para el tratamiento de una presion intraocular elevada.
AU6851696A (en) Compositions containing hydroperoxyeicosatetraenoic acid derivatives and methods of use in treating dry eye disorders
PT840601E (pt) Thip para o tratamento de desordens do sono
BR0013935A (pt) IsÈmeros oticamente ativos de cetotifeno e metabólitos terapeuticamente ativos dos mesmos
GR3031917T3 (en) Treatment of diseases caused by sebaceous gland disorders with acyl CoA cholesterol acyl transferase inhibitors
FR2735369B1 (fr) Compositions pharmaceutiques a base de sel de sodium du diclofenac et de thiocolchicoside
NO996468L (no) Anvendelse av gaba-analoger slik som gabapentin i fremstillingen av et medikament for behandling av betennelsessykdommer
DK0615443T3 (da) Lægemiddel i akut virksom form indeholdende Flurbiprofen og anvendelse deraf
BR9809673A (pt) Derivados de triptolida úteis no tratamento de doenças autoimunes
SE9504267D0 (sv) New therapeutic use
ATE120447T1 (de) Polyamin-derivate als antineoplastische mittel.
ES2186153T3 (es) Sulfato de 5-alfa-pregnan-3-beta-ol-20-ona para el tratamiento de tumores y de los trastornos del snc.
BR0012121A (pt) Derivado de aminotetralina para terapia de doenças cardiovasculares
DK0425109T3 (da) 3-substitueret-2-oxindolderivater som inhibitorer for interleukin-1-biosyntese
MX9704887A (es) Composiciones farmaceuticas para el tratamiento de trastornos depresivos.
IT1291307B1 (it) Composizione farmaceutica atta al trattamento delle patologie neurodegenerative
CA2237335A1 (en) The use of cholinesterase inhibitors in the treatment of xerostomia